{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:01:44Z","timestamp":1791162104453,"version":"4.1.0"},"reference-count":172,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["SC1CA193758"],"award-info":[{"award-number":["SC1CA193758"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA118638"],"award-info":[{"award-number":["U54CA118638"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1810429"],"award-info":[{"award-number":["W81XWH1810429"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Ovarian cancer (OvCa) is a destructive malignancy due to difficulties in early detection and late advanced-stage diagnoses, leading to high morbidity and mortality rates for women. Currently, the quality treatment for OvCa includes tumor debulking surgery and intravenous platinum-based chemotherapy. However, numerous patients either succumb to the disease or undergo relapse due to drug resistance, such as to platinum drugs. There are several mechanisms that cause cancer cells\u2019 resistance to chemotherapy, such as inactivation of the drug, alteration of the drug targets, enhancement of DNA repair of drug-induced damage, and multidrug resistance (MDR). Some targeted therapies, such as nanoparticles, and some non-targeted therapies, such as natural products, reverse MDR. Nanoparticle targeting can lead to the reversal of MDR by allowing direct access for agents to specific tumor sites. Natural products have many anti-cancer properties that adversely regulate the factors contributing to MDR. The present review displays the current problems in OvCa treatments that lead to resistance and proposes using nanotechnology and natural products to overcome drug resistance.<\/jats:p>","DOI":"10.3390\/cancers13215480","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T11:47:38Z","timestamp":1635767258000},"page":"5480","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers"],"prefix":"10.3390","volume":"13","author":[{"given":"Melayshia","family":"McFadden","sequence":"first","affiliation":[{"name":"Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Oprea-Ilies","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0397-3794","authenticated-orcid":false,"given":"Rajesh","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA"},{"name":"Cancer Health Equity Institute, Morehouse School of Medicine, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,31]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society (2021). Ovarian Cancer Statistics: How Common Is Ovarian Cancer, American Cancer Society."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Singh, S.K., Apata, T., Singh, S., McFadden, M., and Singh, R. (2021). Clinical implication of metformin in relation to diabetes mellitus and ovarian cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9081020"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2003.10.019","article-title":"Granulosa cell tumor of the ovary","volume":"21","author":"Schumer","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/annonc\/mds315","article-title":"Optimal first-line treatment in ovarian cancer","volume":"23","author":"Raja","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1002\/cam4.2560","article-title":"Ovarian cancer: Current status and strategies for improving therapeutic outcomes","volume":"8","author":"Chandra","year":"2019","journal-title":"Cancer Med."},{"key":"ref_7","unstructured":"National Cancer Institute (2016). SEER Cancer Statistics Review, National Cancer Institute."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13048-020-00679-8","article-title":"Anti-proliferative activities of Byrsocarpus coccineus Schum. and Thonn. (Connaraceae) using ovarian cancer cell lines","volume":"13","author":"Ukwade","year":"2020","journal-title":"J. Ovarian Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: A brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2015.03.001","article-title":"Prediction of drug-ABC-transporter interaction\u2014Recent advances and future challenges","volume":"86","author":"Montanari","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/jps.23952","article-title":"PARP Inhibitors as P-glyoprotein Substrates","volume":"103","author":"Lawlor","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.2174\/15680096113139990082","article-title":"Small molecule inhibitors of multidrug resistance gene (MDR1) expression: Preclinical evaluation and mechanisms of action","volume":"13","author":"Santos","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Paterson","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kenicer, J., Spears, M., Lyttle, N., Taylor, K.J., Liao, L., Cunningham, C.A., Lambros, M., MacKay, A., Yao, C., and Reis-Filho, J. (2014). Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-762"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jjco\/hyaa015","article-title":"Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer","volume":"50","author":"Nishio","year":"2020","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-018-0063-0","article-title":"Tumor evolution and chemoresistance in ovarian cancer","volume":"2","author":"Kim","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"ref_19","first-page":"S161","article-title":"Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2007.11.004","article-title":"Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer","volume":"108","author":"Salani","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_21","first-page":"111","article-title":"Surgical debulking of ovarian cancer: What difference does it make?","volume":"3","author":"Schorge","year":"2010","journal-title":"Rev. Obstet. Gynecol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO)","volume":"115","author":"Reuss","year":"2009","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/annonc\/mdt465","article-title":"State of the art of surgery in advanced epithelial ovarian cancer","volume":"24","author":"Hacker","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cncr.28508","article-title":"Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer","volume":"120","author":"Wright","year":"2014","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/ijgc-00009577-200401000-00005","article-title":"Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer","volume":"14","author":"Brockbank","year":"2004","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2015.11.022","article-title":"Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: An external validation study of three models using computed tomography","volume":"140","author":"Rutten","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_28","first-page":"11","article-title":"Recommendation of the Polish society of oncological gynaecology on the diagnosis and treatment of epithelial ovarian cancer","volume":"11","author":"Basta","year":"2015","journal-title":"Oncol. Clin. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000338532","article-title":"Favorable response of heavily treated Wilms\u2019 tumor to paclitaxel and carboplatin","volume":"35","author":"Ozaki","year":"2012","journal-title":"Onkologie"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1758834010361333","article-title":"Practical considerations in ovarian cancer chemotherapy","volume":"2","author":"Cristea","year":"2010","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/02841860119644","article-title":"A systematic overview of chemotherapy effects in ovarian cancer","volume":"40","author":"Glimelius","year":"2001","journal-title":"Acta Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/bjc.1998.710","article-title":"Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists\u2019 Group","volume":"78","author":"Aabo","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1179299X19860815","DOI":"10.1177\/1179299X19860815","article-title":"Chemotherapy resistance in advanced ovarian cancer patients","volume":"11","author":"Pokhriyal","year":"2019","journal-title":"Biomark Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Damia, G., and Broggini, M. (2019). Platinum Resistance in Ovarian Cancer: Role of DNA Repair. Cancers, 11.","DOI":"10.3390\/cancers11010119"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: What is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1992.10.11.1748","article-title":"Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma","volume":"10","author":"Einzig","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"ref_39","first-page":"96","article-title":"Taxanes, microtubules and chemoresistant breast cancer","volume":"1785","author":"McGrogan","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4161\/cc.11.2.18737","article-title":"Monitoring APC\/C activity in the presence of chromosomal misalignment in unperturbed cell populations","volume":"11","author":"Schnerch","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11497","DOI":"10.2147\/OTT.S195552","article-title":"Role of olaparib as maintenance treatment for ovarian cancer: The evidence to date","volume":"12","author":"Montemorano","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"53ra75","DOI":"10.1126\/scitranslmed.3001538","article-title":"PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors","volume":"2","author":"Dedes","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cell.2006.11.042","article-title":"Essential role for nuclear PTEN in maintaining chromosomal integrity","volume":"128","author":"Shen","year":"2007","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: The underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-9966-31-14","article-title":"Therapeutic strategies in epithelial ovarian cancer","volume":"31","author":"Kim","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"64607","DOI":"10.18632\/oncotarget.19929","article-title":"CAR-T cell therapy in ovarian cancer: From the bench to the bedside","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_50","first-page":"1934","article-title":"Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer","volume":"51","author":"Aoki","year":"1991","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"718","DOI":"10.7150\/ijbs.14405","article-title":"New strategies for the treatment of solid tumors with CAR-T cells","volume":"12","author":"Zhang","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-14-2458","article-title":"Trafficking of T cells into tumors","volume":"74","author":"Slaney","year":"2014","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cellimm.2012.07.001","article-title":"Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors","volume":"278","author":"Park","year":"2012","journal-title":"Cell. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"672502","DOI":"10.3389\/fimmu.2021.672502","article-title":"T-cell receptor therapy in the treatment of ovarian cancer: A mini review","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1533033819831068","DOI":"10.1177\/1533033819831068","article-title":"The emerging world of TCR-T cell trials against cancer: A systematic review","volume":"18","author":"Zhang","year":"2019","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Mehta, K., and Fok, J. (2009). Targeting transglutaminase-2 to overcome chemoresistance in cancer cells. Drug Resistance in Cancer Cells, Springer.","DOI":"10.1007\/978-0-387-89445-4_5"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: An overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"650","DOI":"10.21037\/tcr.2016.08.40","article-title":"TP53 mutations in epithelial ovarian cancer","volume":"5","author":"Zhang","year":"2016","journal-title":"Transl. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ijc.10226","article-title":"Cancer chemoresistance: The relationship between p53 and multidrug transporters","volume":"98","author":"Bush","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nm0796-811","article-title":"Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients","volume":"2","author":"Aas","year":"1996","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/1568009033481967","article-title":"Taxanes: Microtubule and centrosome targets, and cell cycle dependent mechanisms of action","volume":"3","author":"Abal","year":"2003","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"23875","DOI":"10.1074\/jbc.274.34.23875","article-title":"A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance","volume":"274","author":"Chang","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1470-2045(04)01411-1","article-title":"Do beta-tubulin mutations have a role in resistance to chemotherapy?","volume":"5","author":"Berrieman","year":"2004","journal-title":"Lancet. Oncol."},{"key":"ref_68","first-page":"5803","article-title":"Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells","volume":"61","author":"Kavallaris","year":"2001","journal-title":"Cancer Res."},{"key":"ref_69","first-page":"7248","article-title":"Biochemical genetic analysis of indanocine resistance in human leukemia","volume":"61","author":"Hua","year":"2001","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/1535-7163.MCT-05-0190","article-title":"Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules","volume":"5","author":"Hari","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_71","first-page":"1207","article-title":"Elevated levels of microtubule destabilizing factors in a Taxol-resistant\/dependent A549 cell line with an alpha-tubulin mutation","volume":"63","author":"Martello","year":"2003","journal-title":"Cancer Res."},{"key":"ref_72","first-page":"259","article-title":"Trastuzumab (Herceptin) and breast cancer: Mechanisms of resistance","volume":"94","author":"Dieras","year":"2007","journal-title":"Bull. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Casado","year":"2004","journal-title":"Cancer Treat. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":"Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.1038\/sj.onc.1209088","article-title":"The Akt\/PKB pathway: Molecular target for cancer drug discovery","volume":"24","author":"Cheng","year":"2005","journal-title":"Oncogene"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A family of drug transporters: The multidrug resistance-associated proteins","volume":"92","author":"Borst","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fphar.2013.00028","article-title":"Mechanisms and insights into drug resistance in cancer","volume":"4","author":"Zahreddine","year":"2013","journal-title":"Front. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","article-title":"The role of glutathione-S-transferase in anti-cancer drug resistance","volume":"22","author":"Townsend","year":"2003","journal-title":"Oncogene"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"11653","DOI":"10.1074\/jbc.M011294200","article-title":"Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes","volume":"276","author":"Sauna","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1158\/0008-5472.CAN-03-3111","article-title":"Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): Resistance to docetaxel","volume":"64","author":"Chen","year":"2004","journal-title":"Cancer Res."},{"key":"ref_83","first-page":"4559","article-title":"Overexpression of the BCRP\/MXR\/ABCP gene in a topotecan-selected ovarian tumor cell line","volume":"59","author":"Maliepaard","year":"1999","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Fontana, F., Carollo, E., Melling, G.E., and Carter, D.R.F. (2021). Extracellular vesicles: Emerging modulators of cancer drug resistance. Cancers, 13.","DOI":"10.3390\/cancers13040749"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"11150","DOI":"10.1038\/ncomms11150","article-title":"Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1","volume":"7","author":"Co","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/iub.2215","article-title":"Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons","volume":"72","author":"Majidinia","year":"2020","journal-title":"IUBMB Life"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1158\/1535-7163.MCT-07-0019","article-title":"Therapeutic ultrasound facilitates antiangiogenic gene delivery and inhibits prostate tumor growth","volume":"6","author":"Benny","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jconrel.2013.11.018","article-title":"Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome-microbubble complexes assisted by ultrasound","volume":"174","author":"Deng","year":"2014","journal-title":"J. Controll. Release"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ejmech.2017.01.020","article-title":"Coumarin derivatives as potential antitumor agents: Growth inhibition, apoptosis induction and multidrug resistance reverting activity","volume":"127","author":"Bisi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1039\/C7CS00550D","article-title":"Dendrimers in combination with natural products and analogues as anti-cancer agents","volume":"47","author":"Mignani","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"ref_91","first-page":"2316","article-title":"Piperine alkaloid induces anticancer and apoptotic effects in cisplatin resistant ovarian carcinoma by inducing G2\/M phase cell cycle arrest, caspase activation and inhibition of cell migration and PI3K\/Akt\/GSK3\u03b2 signalling pathway","volume":"24","author":"Qiu","year":"2019","journal-title":"Off. J. Balkan Union Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cbi.2019.01.008","article-title":"Quercetin inhibits human metastatic ovarian cancer cell growth and modulates components of the intrinsic apoptotic pathway in PA-1 cell line","volume":"300","author":"Teekaraman","year":"2019","journal-title":"Chem. -Biol. Interact."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13048-020-00731-7","article-title":"Therapeutic role of curcumin and its novel formulations in gynecological cancers","volume":"13","author":"Pourhanifeh","year":"2020","journal-title":"J. Ovarian Res."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Lang, F., Qin, Z., Li, F., Zhang, H., Fang, Z., and Hao, E. (2015). Apoptotic cell death induced by resveratrol is partially mediated by the autophagy pathway in human ovarian cancer cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129196"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1097\/IGC.0000000000001064","article-title":"The effect of thymoquinone on apoptosis of SK-OV-3 ovarian cancer cell by regulation of Bcl-2 and bax","volume":"27","author":"Liu","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"188314","DOI":"10.1016\/j.bbcan.2019.188314","article-title":"Challenges in liver cancer and possible treatment approaches","volume":"1873","author":"Anwanwan","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/leu.2013.270","article-title":"DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia","volume":"28","author":"Stevenson","year":"2014","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/j.foodchem.2013.04.125","article-title":"Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells","volume":"141","author":"Do","year":"2013","journal-title":"Food Chem."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Wojtowicz, K., Sterzy\u0144ska, K., \u015awierczewska, M., Nowicki, M., Zabel, M., and Januchowski, R. (2021). Piperine targets different drug resistance mechanisms in human ovarian cancer cell lines leading to increased sensitivity to cytotoxic drugs. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084243"},{"key":"ref_100","first-page":"2","article-title":"Bioflavonoids classification, pharmacological, biochemical effects and therapeutic POTENTIAL","volume":"33","author":"Narayana","year":"2001","journal-title":"Indian J. Pharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fonc.2019.00487","article-title":"Reversal of multidrug resistance in cancer by multi-functional flavonoids","volume":"9","author":"Ye","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.bcp.2004.07.009","article-title":"Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder","volume":"68","author":"Chearwae","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tox.2009.11.008","article-title":"Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto- and DNA-protective dietary compounds","volume":"278","author":"Bisht","year":"2010","journal-title":"Toxicology"},{"key":"ref_104","first-page":"141","article-title":"Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical research","volume":"14","author":"Jurenka","year":"2009","journal-title":"Altern. Med. Rev."},{"key":"ref_105","first-page":"363","article-title":"Anticancer potential of curcumin: Preclinical and clinical studies","volume":"23","author":"Aggarwal","year":"2003","journal-title":"Anticancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-0-387-46401-5_4","article-title":"Modulation of transcription factors by curcumin","volume":"595","author":"Shishodia","year":"2007","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2741\/e798","article-title":"Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer","volume":"9","author":"Banerjee","year":"2017","journal-title":"Front. Biosci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ejmech.2017.06.047","article-title":"Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer","volume":"138","author":"Joshi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11010-006-9302-8","article-title":"Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin","volume":"296","author":"Limtrakul","year":"2007","journal-title":"Mol. Cell. Biochem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00280-005-0052-1","article-title":"Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1)","volume":"57","author":"Chearwae","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1158\/1535-7163.MCT-06-0087","article-title":"Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin","volume":"5","author":"Chearwae","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2174\/138920111795163887","article-title":"Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy","volume":"12","author":"Wu","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ijc.20160","article-title":"In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells","volume":"111","author":"Odot","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1440-1681.2011.05648.x","article-title":"Discovery of curcumin, a component of golden spice, and its miraculous biological activities","volume":"39","author":"Gupta","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1749-6632.2002.tb02918.x","article-title":"Cancer chemopreventive activity of resveratrol","volume":"957","author":"Bhat","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1089\/152308601317203567","article-title":"Biological effects of resveratrol","volume":"3","author":"Bhat","year":"2001","journal-title":"Antioxid. Redox Signal."},{"key":"ref_117","first-page":"865","article-title":"Antiproliferative effect of synthetic resveratrol on human breast epithelial cells","volume":"12","author":"Mgbonyebi","year":"1998","journal-title":"Int. J. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/0008-5472.CAN-03-2404","article-title":"Resveratrol-induced autophagocytosis in ovarian cancer cells","volume":"64","author":"Opipari","year":"2004","journal-title":"Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2741\/s544","article-title":"Role of natural compounds in preventing and treating breast cancer","volume":"12","author":"Noel","year":"2020","journal-title":"Front. Biosci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"17216","DOI":"10.18632\/oncotarget.15303","article-title":"Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53\/ p21WAF1\/CIP1 and p27KIP1 pathway","volume":"8","author":"Singh","year":"2017","journal-title":"Oncotarget"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Ko, J.-H., Sethi, G., Um, J.-Y., Shanmugam, M.K., Arfuso, F., Kumar, A.P., Bishayee, A., and Ahn, K.S. (2017). The role of resveratrol in cancer therapy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122589"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"R209","DOI":"10.1530\/ERC-13-0171","article-title":"Resveratrol and cancer: Focus on in vivo evidence","volume":"21","author":"Carter","year":"2014","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/CMAR.S4544","article-title":"Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer","volume":"1","author":"Nguyen","year":"2009","journal-title":"Cancer Manag. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1158\/1940-6207.CAPR-11-0148","article-title":"Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases\u2014Safety, pharmacokinetics, and pharmacodynamics","volume":"4","author":"Howells","year":"2011","journal-title":"Cancer Prev. Res."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Singh, S.K., Apata, T., Gordetsky, J.B., and Singh, R. (2019). Docetaxel combined with thymoquinone induces apoptosis in prostate cancer cells via inhibition of the PI3K\/AKT signaling pathway. Cancers, 11.","DOI":"10.3390\/cancers11091390"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ccr.2004.09.003","article-title":"Nuclear factor-kappaB: The enemy within","volume":"6","author":"Aggarwal","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1541-7786.MCR-07-2088","article-title":"Targeting nuclear factor-kappa B activation pathway by thymoquinone: Role in suppression of antiapoptotic gene products and enhancement of apoptosis","volume":"6","author":"Sethi","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2221-1691(13)60075-1","article-title":"A review on therapeutic potential of Nigella sativa: A miracle herb","volume":"3","author":"Ahmad","year":"2013","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"724658","DOI":"10.1155\/2014\/724658","article-title":"Therapeutic implications of black seed and its constituent thymoquinone in the prevention of cancer through inactivation and activation of molecular pathways","volume":"2014","author":"Rahmani","year":"2014","journal-title":"Evidence-Based Complement. Altern. Med."},{"key":"ref_131","first-page":"117","article-title":"Thymoquinone in the clinical treatment of cancer: Fact or fiction?","volume":"7","author":"Abukhader","year":"2013","journal-title":"Pharm. Rev."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fphar.2017.00295","article-title":"Thymoquinone as a potential adjuvant therapy for cancer treatment: Evidence from preclinical studies","volume":"8","author":"Mostofa","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","article-title":"Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance","volume":"7","author":"Yao","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"F605","DOI":"10.1152\/ajprenal.00171.2004","article-title":"Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: Effects of molecular size, shape, charge, and deformability","volume":"288","author":"Venturoli","year":"2005","journal-title":"Am. J. Physiol.\u2013Renal Physiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11095-008-9697-x","article-title":"Intravascular delivery of particulate systems: Does geometry really matter?","volume":"26","author":"Decuzzi","year":"2009","journal-title":"Pharm. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12951-019-0562-3","article-title":"Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis","volume":"18","author":"Wang","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1021\/nl900031y","article-title":"Mediating tumor targeting efficiency of nanoparticles through design","volume":"9","author":"Perrault","year":"2009","journal-title":"Nano Lett."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1021\/acsnano.7b09041","article-title":"Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination","volume":"12","author":"Yang","year":"2018","journal-title":"ACS Nano"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","article-title":"In vivo delivery of miRNAs for cancer therapy: Challenges and strategies","volume":"81","author":"Chen","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijpharm.2004.07.019","article-title":"The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs","volume":"284","author":"Kipp","year":"2004","journal-title":"Int. J. Pharm."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1021\/nn800275r","article-title":"Self-assembled lipid\u2212polymer hybrid nanoparticles: A robust drug delivery platform","volume":"2","author":"Zhang","year":"2008","journal-title":"ACS Nano"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Levit, S., and Tang, C. (2021). Polymeric nanoparticle delivery of combination therapy with synergistic effects in ovarian cancer. Nanomaterials, 11.","DOI":"10.3390\/nano11041048"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.biomaterials.2007.01.014","article-title":"Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles","volume":"28","author":"Lee","year":"2007","journal-title":"Biomaterials"},{"key":"ref_145","first-page":"7497","article-title":"Pegylated liposomal-paclitaxel induces ovarian cancer cell apoptosis via TNF-induced ERK\/AKT signaling pathway","volume":"17","author":"Qi","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"118914","DOI":"10.1016\/j.lfs.2020.118914","article-title":"Nanotechnology in ovarian cancer: Diagnosis and treatment","volume":"266","author":"Barani","year":"2021","journal-title":"Life Sci."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Xiao, X., Zou, J., Fang, Y., Meng, Y., Xiao, C., Fu, J., Liu, S., Bai, P., and Yao, Y. (2018). Fisetin and polymeric micelles encapsulating fisetin exhibit potent cytotoxic effects towards ovarian cancer cells. BMC Complement. Altern. Med., 18.","DOI":"10.1186\/s12906-018-2127-7"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.biomaterials.2019.04.006","article-title":"Cumulative directional calcium gluing between phosphate and silicate: A facile, robust and biocompatible strategy for siRNA delivery by amine-free non-positive vector","volume":"209","author":"Choi","year":"2019","journal-title":"Biomaterials"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.biomaterials.2014.10.044","article-title":"Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment","volume":"37","author":"Cai","year":"2015","journal-title":"Biomaterials"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s11095-014-1602-1","article-title":"Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer","volume":"32","author":"Yang","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2018.04.017","article-title":"Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer","volume":"427","author":"Singh","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: Role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.1002\/jcp.26595","article-title":"Quercetin: A functional dietary flavonoid with potential chemo-preventive properties in colorectal cancer","volume":"233","author":"Darband","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","article-title":"Insoluble drug delivery strategies: Review of recent advances and business prospects","volume":"5","author":"Kalepu","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_155","first-page":"159","article-title":"Nanodrug delivery in reversing multidrug resistance in cancer cells","volume":"5","author":"Govender","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Feng, S.T., Li, J., Luo, Y., Yin, T., Cai, H., Wang, Y., Dong, Z., Shuai, X., and Li, Z.P. (2014). pH-sensitive nanomicelles for controlled and efficient drug delivery to human colorectal carcinoma LoVo cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100732"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.2147\/IJN.S140325","article-title":"Drug delivery approaches for breast cancer","volume":"12","author":"Singh","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1208\/s12249-014-0113-z","article-title":"Polymeric micelles: Nanocarriers for cancer-targeted drug delivery","volume":"15","author":"Zhang","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Paris, J.L., and Vallet-Reg\u00ed, M. (2020). Mesoporous silica nanoparticles for co-delivery of drugs and nucleic acids in oncology: A review. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060526"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Chauhan, A.S. (2018). Dendrimers for drug delivery. Molecules, 23.","DOI":"10.3390\/molecules23040938"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Janaszewska, A., Lazniewska, J., Trzepi\u0144ski, P., Marcinkowska, M., and Klajnert-Maculewicz, B. (2019). Cytotoxicity of dendrimers. Biomolecules, 9.","DOI":"10.3390\/biom9080330"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s11095-013-1290-2","article-title":"Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7\/Adr cells","volume":"31","author":"Mussi","year":"2014","journal-title":"Pharm. Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/1061186X.2015.1086358","article-title":"Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance","volume":"24","author":"Liu","year":"2016","journal-title":"J. Drug Target."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/2472630318816668","article-title":"siRNA-conjugated nanoparticles to treat ovarian cancer","volume":"24","author":"Halbur","year":"2019","journal-title":"SLAS Technol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1158\/1535-7163.MCT-14-0556","article-title":"Multifunctional polymeric micelles co-loaded with anti-survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer","volume":"14","author":"Salzano","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_166","first-page":"3823","article-title":"Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin","volume":"7","author":"Zou","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1368-7646(02)00049-3","article-title":"Survivin expression and resistance to anticancer treatments: Perspectives for new therapeutic interventions","volume":"5","author":"Zaffaroni","year":"2002","journal-title":"Drug Resist. Updat."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00018-002-8518-3","article-title":"Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer","volume":"59","author":"Zaffaroni","year":"2002","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","article-title":"Nanoparticle-based targeted drug delivery","volume":"86","author":"Singh","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Persano, S., Das, P., and Pellegrino, T. (2021). Magnetic nanostructures as emerging therapeutic tools to boost anti-tumour immunity. Cancers, 13.","DOI":"10.3390\/cancers13112735"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Singh, S.K., Gordetsky, J.B., Bae, S., Acosta, E.P., Lillard, J.W., and Singh, R. (2020). Selective targeting of the hedgehog signaling pathway by PBM nanoparticles in docetaxel-resistant prostate cancer. Cells, 9.","DOI":"10.3390\/cells9091976"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1158\/1538-7445.AM2018-4665","article-title":"Abstract 4665: Neurotensin receptor-based targeted delivery of thymoquinone for non-small cell lung cancer","volume":"78","author":"Singh","year":"2018","journal-title":"Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5480\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:23:45Z","timestamp":1760167425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/21\/5480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":172,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cancers13215480"],"URL":"https:\/\/doi.org\/10.3390\/cancers13215480","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,31]]}}}